Analysis of second-line therapy in patients with prior pneumonitis receiving first-line combination immunotherapy for advanced non-small cell lung cancer
Second-line cytotoxic chemotherapy following combination immunotherapy may be associated with shorter survival and increased pulmonary toxicity in NSCLC patients with prior CIP. Careful clinical decision-making, multidisciplinary consultation, and close monitoring are essential when initiating second-line treatment in this population.
Authors
- Toyoshi Yanagihara (ORCID: https://orcid.org/0000-0002-2212-0631)
- Yuki Shundo (ORCID: https://orcid.org/0000-0003-3459-951X)
- Makoto Fujimoto (ORCID: https://orcid.org/0000-0002-8151-4913)
- Noriyuki Ebi (ORCID: https://orcid.org/0000-0003-3140-4748)
- Masaki Fujita (ORCID: https://orcid.org/0000-0003-1209-1272)
- Maiya Chen
- Andréa Harumy de Lima Hirata (ORCID: https://orcid.org/0000-0001-7797-424X)
- Hiroyuki Inoue (ORCID: https://orcid.org/0000-0002-8071-8797)
- Takato Ikeda (ORCID: https://orcid.org/0000-0003-3300-6225)
- Yasunori Sakaki
- Natsumi Kushima
Institutions
- Fukuoka University Hospital (JP)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tlcr-2025-762
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00